A new analysis from QuintilesIMS, which draws on the Medicines Use and Spending in the U.S. — A Review of 2016 and Outlook to 2021 report and the Outlook for Global Medicines Through 2021: Balancing Cost and Value, takes an in-depth look at the true drivers of US medicine spending.
Many patients are struggling to access the medicine they need and have important questions about their medicine costs. But, in order to have productive conversations, we need to be using the same set of facts. According to QuintilesIMS, medicine spending growth was just 4.8% in 2016. Unfortunately it doesn’t feel that way for patients. That is because insurers are increasingly using high deductibles, which result in patients paying the full list price of a medicine, even if their insurer receives a significant discount.
Here are four things you should know about the latest QuintilesIMS report:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze